Efficacy of Anakinra in Pericarditis: A Systematic Review

Inflammation of the pericardium is referred to as pericarditis, which can cause sharp chest pain and has a high chance of recurrence even after treatment. This review will explore anakinra, which is an interleukin-1 receptor antagonist, as a potential new treatment for pericarditis. The systematic r...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheema, Ameer Haider, Chaludiya, Keyur, Khalid, Maham, Nwosu, Marcellina, Konka, Srujana, Agyeman, Walter Y, Bisht, Aakash, Gopinath, Ankit, Arcia Franchini, Ana P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531702/
https://www.ncbi.nlm.nih.gov/pubmed/36212270
http://dx.doi.org/10.7759/cureus.29862
Descripción
Sumario:Inflammation of the pericardium is referred to as pericarditis, which can cause sharp chest pain and has a high chance of recurrence even after treatment. This review will explore anakinra, which is an interleukin-1 receptor antagonist, as a potential new treatment for pericarditis. The systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines by searching PubMed and GoogleScholar from the years 2012 to 2022. After applying inclusion and exclusion criteria, thorough screening, and quality appraisal, a total of eleven studies were included in the review; eight case reports and three clinical trials. All studies showed that 100 mg/day of anakinra caused a remarkable improvement in patient outcomes. In addition, the pericarditis resolved quicker and had a lower chance of recurrence in comparison to conventional therapy. 

Ejemplares similares